BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37942683)

  • 1. Asymmetry of thalamic hypometabolism on FDG-PET/CT in neurofibromatosis type 1: Association with peripheral tumor burden.
    Özden C; Mautner VF; Farschtschi S; Molwitz I; Ristow I; Bannas P; Well L; Klutmann S; Adam G; Apostolova I; Buchert R
    J Neuroimaging; 2024; 34(1):138-144. PubMed ID: 37942683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT.
    Salamon J; Papp L; Tóth Z; Laqmani A; Apostolova I; Adam G; Mautner VF; Derlin T
    PLoS One; 2015; 10(12):e0143305. PubMed ID: 26625155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.
    Salamon J; Derlin T; Bannas P; Busch JD; Herrmann J; Bockhorn M; Hagel C; Friedrich RE; Adam G; Mautner VF
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):685-92. PubMed ID: 23232507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Ahlawat S; Blakeley JO; Rodriguez FJ; Fayad LM
    Neurology; 2019 Sep; 93(11):e1076-e1084. PubMed ID: 31395668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
    Salamon J; Veldhoen S; Apostolova I; Bannas P; Yamamura J; Herrmann J; Friedrich RE; Adam G; Mautner VF; Derlin T
    Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced thalamic 18F-flurodeoxyglucose retention in adults with neurofibromatosis type 1.
    Buchert R; von Borczyskowski D; Wilke F; Gronowsky M; Friedrich RE; Brenner W; Mester J; Clausen M; Mautner VF
    Nucl Med Commun; 2008 Jan; 29(1):17-26. PubMed ID: 18049093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
    Urban T; Lim R; Merker VL; Muzikansky A; Harris GJ; Kassarjian A; Bredella MA; Plotkin SR
    Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does elevated glucose metabolism correlate with higher cell density in Neurofibromatosis type 1 associated peripheral nerve sheath tumors?
    Berzaczy D; Mayerhoefer ME; Azizi AA; Haug AR; Senn D; Beitzke D; Weber M; Traub-Weidinger T
    PLoS One; 2017; 12(12):e0189093. PubMed ID: 29206885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Derlin T; Tornquist K; Münster S; Apostolova I; Hagel C; Friedrich RE; Wedegärtner U; Mautner VF
    Clin Nucl Med; 2013 Jan; 38(1):e19-25. PubMed ID: 23242059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral glucose metabolism in adults with neurofibromatosis type 1.
    Apostolova I; Derlin T; Salamon J; Amthauer H; Granström S; Brenner W; Mautner VF; Buchert R
    Brain Res; 2015 Nov; 1625():97-101. PubMed ID: 26335059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
    Benz MR; Czernin J; Dry SM; Tap WD; Allen-Auerbach MS; Elashoff D; Phelps ME; Weber WA; Eilber FC
    Cancer; 2010 Jan; 116(2):451-8. PubMed ID: 19924789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of
    Cook GJR; Lovat E; Siddique M; Goh V; Ferner R; Warbey VS
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1845-1852. PubMed ID: 28589254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.
    Brahmi M; Thiesse P; Ranchere D; Mognetti T; Pinson S; Renard C; Decouvelaere AV; Blay JY; Combemale P
    PLoS One; 2015; 10(10):e0138386. PubMed ID: 26445379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
    Salamon J; Mautner VF; Adam G; Derlin T
    Rofo; 2015 Dec; 187(12):1084-92. PubMed ID: 26333104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
    Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
    J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
    Meany H; Dombi E; Reynolds J; Whatley M; Kurwa A; Tsokos M; Salzer W; Gillespie A; Baldwin A; Derdak J; Widemann B
    Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalamic abnormalities in children with continuous spike-wave during slow-wave sleep: An F-18-fluorodeoxyglucose positron emission tomography perspective.
    Agarwal R; Kumar A; Tiwari VN; Chugani H
    Epilepsia; 2016 Feb; 57(2):263-71. PubMed ID: 26697846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.